查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球流感市场
市场调查报告书
商品编码
1724763

全球流感市场

The Global Influenza Market
出版日期: | 出版商: BCC Research | 英文 188 Pages | 订单完成后即时交付

价格

全球流感市场规模预计将从 2024 年的 90 亿美元成长到 2029 年底的 128 亿美元，在 2024-2029 年预测期内的复合年增长率为 7.2%。

预计北美市场将从 2024 年的 45 亿美元扩大到 2029 年的 63 亿美元，同期的复合年增长率为 7.3%。预计 2024 年欧洲市场价值将达到 24 亿美元，到 2029 年将达到 33 亿美元，复合年增长率为 6.8%。

本报告调查了全球流感市场，并提供了市场概况的摘要、市场影响因素和市场机会的分析、法律制度、新兴技术和技术发展的趋势、市场规模的趋势和预测、各个细分市场和地区的详细分析、竞争格局以及主要企业的概况。

目录

第一章执行摘要

  • 市场展望
  • 研究范围
  • 市场摘要

第二章 市场概述

  • 概述
  • 疫情情景
  • 波特五力分析
  • 供应链分析
  • 宏观经济因素分析
  • 中美贸易战的影响
  • 全球经济成长
  • 人口趋势
  • 公共卫生危机和流行病

第三章 市场动态

  • 市场动态
  • 关键要点
  • 市场驱动因素
  • 快速检测和分子技术的开发
  • 政府对新治疗方法和诊断方法的支持和资助
  • 提高大众对流感疫苗的认识
  • 市场限制
  • 治疗市场由有限数量的供应商主导
  • 储存和分发流感疫苗的高成本
  • 市场机会
  • 强大的流感疫苗研发管道
  • 呼吁改善预防、治疗和疫苗的取得途径

第四章 监管情况

  • 概述
  • 流感疫苗法规
  • 美国流感季节的三价疫苗
  • EMA核准的流感疫苗
  • 流感治疗药物的监管现状
  • 流感检测套件的核准流程
  • 敏感度
  • 特异性

第五章新兴趋势与通路分析

  • 概述
  • 流感诊断进展
  • SHINE科技
  • 电化学生物感测器
  • 实验室晶片设备
  • 量子点和萤光奈米粒子
  • 人工智慧在流感诊断中的作用
  • 流感疫苗新技术
  • 通用流感疫苗
  • 基于mRNA的流感疫苗
  • 基于奈米技术的疫苗
  • 贴片疫苗
  • 流感治疗的进展
  • 基于奈米粒子的治疗方法
  • 临床试验中的潜在药物
  • 专利分析
  • 关键要点

第六章市场区隔分析

  • 细分市场
  • 全球流感市场（按产品细分）
  • 流感诊断
  • 流感疫苗
  • 流感药物
  • 地理分布
  • 关键要点
  • 北美洲
  • 欧洲
  • 亚太地区
  • 其他的

第七章 竞争讯息

  • 流感疫苗市场企业市场占有率分析
  • 流感诊断市场企业市场占有率分析
  • 流感治疗药物市场企业市场占有率分析
  • 创业融资与投资格局
  • 主要市场发展

第八章 流感市场的永续性：ESG 视角

  • 概述
  • ESG风险评估
  • 结论

第九章 附录

  • 调查方法
  • 来源
  • 简称
  • 公司简介
  • ABBOTT
  • ASTRAZENECA
  • BD
  • BIOCRYST PHARMACEUTICALS INC.
  • CSL
  • DAIICHI SANKYO CO. LTD.
  • DANAHER CORP.
  • F. HOFFMANN-LA ROCHE LTD.
  • GSK PLC.
  • HOLOGIC INC.
  • QUIDELORTHO CORP.
  • SANOFI
  • SEKISUI DIAGNOSTICS
  • THERMO FISHER SCIENTIFIC INC.
  • VIATRIS INC.
  • 新兴Start-Ups/市场颠覆者
Product Code: PHM049F

The global influenza market is expected to grow from $9.0 billion in 2024 and is projected to reach $12.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.2% during the forecast period of 2024 to 2029.

The North American influenza market is expected to grow from $4.5 billion in 2024 and is projected to reach $6.3 billion by the end of 2029, at a CAGR of 7.3% during the forecast period of 2024 to 2029.

The European influenza market is expected to grow from $2.4 billion in 2024 and is projected to reach $3.3 billion by the end of 2029, at a CAGR of 6.8% during the forecast period of 2024 to 2029.

Report Scope

This report presents qualitative and quantitative data on the current dynamics impacting the global influenza market. It examines the history of various flu pandemics, disease burden and vaccine coverage in several countries. The report thoroughly evaluates the market for influenza vaccines, therapeutics and diagnostics.

Analyses of the most popular products, clinical trials, new product approvals and emerging technologies are also included in the report. The demographics of the major regions-North America, Europe and Asia-Pacific-and their growth prospects are summarized. The profiles of leading companies and the strategies of international businesses involved in the influenza sector are also discussed.

The market size for influenza is categorized into three product segments: vaccines, therapeutics and diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. Diagnostics are divided into rapid and conventional lab tests. Additional growth potential and forecast data are addressed for the influenza market in each product segment for every region.

For market estimates, data are provided for 2023 as the base year, 2024 as the estimated year and forecast from 2025 through 2029.

Report Includes

  • 55 data tables and 70 additional tables
  • An updated overview and in-depth analysis of the global influenza market
  • Analyses of the global market trends, with sales data from 2021-2024, and projections of compound annual growth rates (CAGRs) through 2029
  • Estimates of the actual market size and revenue forecasts, and a corresponding market share analysis by product segment, and region
  • Discussion of the role of major vaccine providers and companion products approved for a wide variety of influenza testing platforms, including adenovirus, SARS, parainfluenza, coronavirus and human metapneumovirus (hMPV)
  • Analysis of the market opportunities through the Porter's Five Forces model and PESTLE analysis, taking into consideration the prevailing micro- and macro environmental factors
  • Insight into the influenza industry structure, government regulations, and key development issues
  • Analysis of the key patent grants and IP aspects
  • A discussion of the industry's ESG challenges and practices of the industry
  • Analysis of the competitive landscape, featuring the leading participants, their current market rankings, and their market shares
  • Profiles of the leading companies, including Danaher Corp., Sanofi, CSL, La Roche Ltd., and Abbott

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary

Chapter 2 Market Overview

  • Overview
  • Pandemic Scenario
  • Porter's Five Forces Analysis in the Influenza Vaccines Market
  • Potential of New Entrants (Moderate)
  • Bargaining Power of Suppliers (Moderate)
  • Bargaining Power of Buyers (Moderate to High)
  • Threat of Substitute Products or Services (Moderate)
  • Industry Rivalry (High)
  • Supply Chain Analysis
  • Vaccine Development
  • Vaccine Manufacturing
  • Storage and Inventory Management
  • Distribution
  • Administration and Immunization
  • Macroeconomic Factors Analysis
  • Impact of U.S.-China Trade War
  • Global Economic Growth
  • Demographic Trends
  • Public Health Crises and Pandemics

Chapter 3 Market Dynamics

  • Market Dynamics
  • Key Takeaways
  • Market Drivers
  • Development of Rapid Tests and Molecular Technologies
  • Government Support and Funding for Novel Therapies and Diagnosis
  • Rising Public Awareness About Flu Vaccines
  • Market Restraints
  • Therapeutic Market Dominated by Limited Suppliers
  • High Cost Associated with Storage and Supply of Flu Vaccines
  • Market Opportunities
  • Robust Pipeline of Influenza Vaccines
  • Demand for Improved Prevention, Treatment and Vaccine Accessibility

Chapter 4 Regulatory Landscape

  • Overview
  • Regulatory Aspects of Influenza Vaccines
  • Use of Trivalent Influenza Vaccines for the 2024-2025 U.S. Influenza Season
  • Influenza Vaccines Approved by EMA
  • Regulatory Scenario of Influenza Drugs
  • Approval Process of Influenza Detection Kit
  • Sensitivity
  • Specificity

Chapter 5 Emerging Trends and Pipeline Analysis

  • Overview
  • Advance in Influenza Diagnosis
  • SHINE Technology
  • Electrochemical Biosensors
  • Wearable Lab-on-a-Chip Devices
  • Quantum Dots and Fluorescent Nanoparticles
  • Role of AI in Influenza Diagnosis
  • Emerging Technologies in Influenza Vaccines
  • Universal Influenza Vaccine
  • mRNA-based Influenza Vaccines
  • Nanotechnology-based Vaccines
  • Patch-based Vaccines
  • Advances in Influenza Therapeutics
  • Nanoparticle-based Therapies
  • Potential Drug Agents in Clinical Trials
  • Patent Analysis
  • Key Takeaways

Chapter 6 Market Segmentation Analysis

  • Segmentation Breakdown
  • Global Influenza Market by Product Segment
  • Influenza Diagnostics
  • Influenza Vaccines
  • Influenza Therapeutics
  • Geographic Breakdown
  • Key Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • Rest of World

Chapter 7 Competitive Intelligence

  • Company Share Analysis of the Influenza Vaccines Market
  • Company Share Analysis of Influenza Diagnostics Market
  • Company Share Analysis of Influenza Therapeutics Market
  • Venture Fundings and Investments Landscape
  • Key Developments in Market

Chapter 8 Sustainability in Influenza Market: ESG Perspective

  • Overview
  • ESG Risk Ratings
  • Conclusion

Chapter 9 Appendix

  • Methodology
  • Sources
  • Abbreviations
  • Company Profiles
  • ABBOTT
  • ASTRAZENECA
  • BD
  • BIOCRYST PHARMACEUTICALS INC.
  • CSL
  • DAIICHI SANKYO CO. LTD.
  • DANAHER CORP.
  • F. HOFFMANN-LA ROCHE LTD.
  • GSK PLC.
  • HOLOGIC INC.
  • QUIDELORTHO CORP.
  • SANOFI
  • SEKISUI DIAGNOSTICS
  • THERMO FISHER SCIENTIFIC INC.
  • VIATRIS INC.
  • Emerging Start-ups/Market Disruptors

List of Tables

  • Summary Table : Global Influenza Market, by Region, Through 2029
  • Table 1 : History of Influenza Pandemics, 1729-2021
  • Table 2 : Confirmed Cases of Influenza, 2022-2024
  • Table 3 : Influenza Vaccines in Clinical Trials, 2024
  • Table 4 : Vaccines Licensed for Use in the U.S., 2024
  • Table 5 : FDA-Approved Influenza Drugs, 1966-2018
  • Table 6 : Approved Influenza Drugs in Other Countries
  • Table 7 : FDA-Approved Influenza Detection Tests, 2024
  • Table 8 : List of Vaccine Pipelines for Influenza Virus-based Platform, 2024
  • Table 9 : List of Vaccine Pipelines for Non-VLP Nanoparticles Platform, 2024
  • Table 10 : List of Vaccine Pipelines for Nucleic Acid-based Platform, 2024
  • Table 11 : List of Vaccine Pipelines for Recombinant Proteins Platform, 2024
  • Table 12 : List of Vaccine Pipelines for Virus-like particles (VLP) Platform, 2024
  • Table 13 : List of Vaccine Pipelines for Virus-vectored Platform, 2024
  • Table 14 : Influenza Drugs in Clinical Trials, 2024
  • Table 15 : List of Several Granted Patents in Influenza Vaccine, 2023-2025
  • Table 16 : List of Several Granted Patents in Influenza Diagnosis Tools, 2023-2025
  • Table 17 : List of Several Granted Patents in Influenza Drugs, 2023-2025
  • Table 18 : Global Influenza Market, by Product Segment, Through 2029
  • Table 19 : Global Influenza Diagnostics Market, by Type, Through 2029
  • Table 20 : Influenza Virus Testing Methods, 2024
  • Table 21 : FDA-Approved Influenza Detection Devices, 2022-2025
  • Table 22 : Global Influenza Diagnostics Market, by Region, Through 2029
  • Table 23 : Influenza Vaccine Products for the 2024-2025 Influenza Season
  • Table 24 : Global Influenza Vaccines Market, by Type, Through 2029
  • Table 25 : Seasonal Influenza Vaccines Pricing, 2024-2025
  • Table 26 : Global Influenza Vaccines Market, by Region, Through 2029
  • Table 27 : Global Influenza Therapeutics Market, by Region, Through 2029
  • Table 28 : Global Influenza Market, by Region, Through 2029
  • Table 29 : North American Influenza Market, by Product Segment, Through 2029
  • Table 30 : North American Influenza Market, by Country, Through 2029
  • Table 31 : Results of Tests Performed by Clinical Laboratories in the U.S., 2020-2024
  • Table 32 : Results of Tests Performed by Clinical Laboratories in the U.S., 2024-2025 Season
  • Table 33 : The U.S. Influenza Market, by Product Segment, Through 2029
  • Table 34 : Number of Influenza Detection in Canada, by Age Group, 2024-2025 Season
  • Table 35 : Canadian Influenza Market, by Product Segment, Through 2029
  • Table 36 : Influenza Vaccination Coverage in Mexico, 2018-2023
  • Table 37 : Mexican Influenza Market, by Product Segment, Through 2029
  • Table 38 : European Influenza Market, by Product Segment, Through 2029
  • Table 39 : European Influenza Market, by Country, Through 2029
  • Table 40 : Influenza Vaccination Coverage in Germany, 2018-2023
  • Table 41 : German Influenza Market, by Product Segment, Through 2029
  • Table 42 : Vaccines Marketed in U.K. for 2024-2025 Influenza Season
  • Table 43 : Influenza Vaccination Coverage in U.K., 2018-2023
  • Table 44 : U.K. Influenza Market, by Product Segment, Through 2029
  • Table 45 : Influenza Vaccination Coverage in France, 2018-2023
  • Table 46 : French Influenza Market, by Product Segment, Through 2029
  • Table 47 : Influenza Vaccines for Use in Pediatrics in Spain, 2024-2025 Season
  • Table 48 : Spanish Influenza Market, by Product Segment, Through 2029
  • Table 49 : Italian Influenza Market, by Product Segment, Through 2029
  • Table 50 : Rest of European Influenza Market, by Product Segment, Through 2029
  • Table 51 : Asia-Pacific Influenza Market, by Product Segment, Through 2029
  • Table 52 : Asia-Pacific Influenza Market, by Country, Through 2029
  • Table 53 : Chinese Influenza Market, by Product Segment, Through 2029
  • Table 54 : Japanese Influenza Market, by Product Segment, Through 2029
  • Table 55 : Indian Influenza Market, by Product Segment, Through 2029
  • Table 56 : Australian Influenza Market, by Product Segment, Through 2029
  • Table 57 : Rest of Asia-Pacific Influenza Market, by Product Segment, Through 2029
  • Table 58 : Rest of World Influenza Market, by Product Segment, Through 2029
  • Table 59 : Rest of World Influenza Market, by Country, Through 2029
  • Table 60 : South American Influenza Market, by Product Segment, Through 2029
  • Table 61 : Middle Eastern and African Influenza Market, by Product Segment, Through 2029
  • Table 62 : Recent Venture Fundings in the Influenza Market, 2024
  • Table 63 : Recent Key Developments in Influenza Market, 2023 and 2024
  • Table 64 : ESG Risk Rankings for Influenza Market Companies, 2025*
  • Table 65 : Report Information Sources
  • Table 66 : Abbreviations Used in the Global Influenza Market
  • Table 67 : Abbott: Company Snapshot
  • Table 68 : Abbott: Financial Performance, FY 2022 and 2023
  • Table 69 : Abbott: Product Portfolio
  • Table 70 : Abbott: News/Key Developments, 2024
  • Table 71 : AstraZeneca: Company Snapshot
  • Table 72 : AstraZeneca: Financial Performance, FY 2022 and 2023
  • Table 73 : AstraZeneca: Product Portfolio
  • Table 74 : AstraZeneca: News/Recent Developments, 2023 and 2024
  • Table 75 : BD: Company Snapshot
  • Table 76 : BD: Financial Performance, FY 2022 and 2023
  • Table 77 : BD: Product Portfolio
  • Table 78 : BD: News/Key Developments, 2021-2023
  • Table 79 : BioCryst Pharmaceuticals Inc.: Company Snapshot
  • Table 80 : BioCryst Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
  • Table 81 : BioCryst Pharmaceuticals Inc.: Product Portfolio
  • Table 82 : CSL: Company Snapshot
  • Table 83 : CSL: Financial Performance, FY 2022 and 2023
  • Table 84 : CSL: Product Portfolio
  • Table 85 : CSL: News/Key Developments, 2022-2024
  • Table 86 : Daiichi Sankyo Co. Ltd.: Company Snapshot
  • Table 87 : Daiichi Sankyo Co. Ltd.: Financial Performance, FY 2022 and 2023
  • Table 88 : Daiichi Sankyo Co. Ltd.: Product Portfolio
  • Table 89 : Daiichi Sankyo Co. Ltd.: News/Key Developments, 2023
  • Table 90 : Danaher Corp.: Company Snapshot
  • Table 91 : Danaher Corp.: Financial Performance, FY 2022 and 2023
  • Table 92 : Danaher Corp.: Product Portfolio
  • Table 93 : Danaher Corp: News/Recent Developments, 2021 and 2022
  • Table 94 : F. Hoffmann-La Roche Ltd.: Company Snapshot
  • Table 95 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
  • Table 96 : F. Hoffmann-La Roche Ltd.: Product Portfolio
  • Table 97 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
  • Table 98 : GSK Plc.: Company Snapshot
  • Table 99 : GSK Plc.: Financial Performance, FY 2022 and 2023
  • Table 100 : GSK Plc.: Product Portfolio
  • Table 101 : GSK Plc.: News/Key Developments, 2024
  • Table 102 : Hologic Inc.: Company Snapshot
  • Table 103 : Hologic Inc.: Financial Performance, FY 2022 and 2023
  • Table 104 : Hologic Inc.: Product Portfolio
  • Table 105 : Hologic Inc.: News/Key Developments, 2022
  • Table 106 : QuidelOrtho Corp.: Company Snapshot
  • Table 107 : QuidelOrtho Corp.: Financial Performance, FY 2022 and 2023
  • Table 108 : QuidelOrtho Corp.: Product Portfolio
  • Table 109 : QuidelOrtho Corp.: News/Key Developments, 2024
  • Table 110 : Sanofi: Company Snapshot
  • Table 111 : Sanofi: Financial Performance, FY 2022 and 2023
  • Table 112 : Sanofi: Product Portfolio
  • Table 113 : Sanofi: News/Key Developments, 2022-2024
  • Table 114 : Sekisui Diagnostics: Company Snapshot
  • Table 115 : Sekisui Diagnostics: Product Portfolio
  • Table 116 : Sekisui Diagnostics: News/Key Developments, 2024
  • Table 117 : Thermo Fisher Scientific Inc.: Company Snapshot
  • Table 118 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
  • Table 119 : Thermo Fisher Scientific Inc.: Product Portfolio
  • Table 120 : Thermo Fisher Scientific Inc.: News/Key Developments, 2021-2023
  • Table 121 : Viatris Inc.: Company Snapshot
  • Table 122 : Viatris Inc.: Financial Performance, FY 2022 and 2023
  • Table 123 : Viatris Inc.: Product Portfolio
  • Table 124 : List of Selected Emerging Startups

List of Figures

  • Summary Figure : Global Influenza Market Shares, by Region, 2023
  • Figure 1 : Porter's Five Forces Analysis of the Influenza Vaccines Market
  • Figure 2 : Supply Chain Analysis of Influenza Vaccine
  • Figure 3 : Market Dynamics of the Global Influenza Market
  • Figure 4 : Clinical Trial Studies of Influenza Vaccines, by Trial Phase, 2024
  • Figure 5 : Global Influenza Market Shares, by Product Segment, 2023
  • Figure 6 : Global Influenza Diagnostics Market Shares, by Type, 2023
  • Figure 7 : FDA-Approval of Influenza Detection Devices, 2015-January 2025
  • Figure 8 : Global Influenza Diagnostics Market Shares, by Region, 2023
  • Figure 9 : Global Influenza Vaccines Market Shares, by Type, 2023
  • Figure 10 : Global Influenza Vaccines Market Shares, by Region, 2023
  • Figure 11 : Global Influenza Therapeutics Market Shares, by Region, 2023
  • Figure 12 : Global Influenza Market Shares, by Region, 2023
  • Figure 13 : North American Influenza Market Shares, by Product Segment, 2023
  • Figure 14 : North American Influenza Market Shares, by Country, 2023
  • Figure 15 : Total Vaccine Doses Distributed in U.S., 2008-2023
  • Figure 16 : Influenza-Positive Tests Reported to the CDC by U.S. Clinical Laboratories, 2024-2025 Season
  • Figure 17 : The U.S. Influenza Market Shares, by Product Segment, 2023
  • Figure 18 : Influenza Detection in Canada, by Age Group and Report Week, 2024-2025 Season
  • Figure 19 : Canadian Influenza Market Shares, by Product Segment, 2023
  • Figure 20 : Mexican Influenza Market Shares, by Product Segment, 2023
  • Figure 21 : European Influenza Market Shares, by Product Segment, 2023
  • Figure 22 : European Influenza Market Shares, by Country, 2023
  • Figure 23 : German Influenza Market Shares, by Product Segment, 2023
  • Figure 24 : U.K. Influenza Market Shares, by Product Segment, 2023
  • Figure 25 : French Influenza Market Shares, by Product Segment, 2023
  • Figure 26 : Spanish Influenza Market Shares, by Product Segment, 2023
  • Figure 27 : Italian Influenza Market Shares, by Product Segment, 2023
  • Figure 28 : Rest of European Influenza Market Shares, by Product Segment, 2023
  • Figure 29 : Asia-Pacific Influenza Market Shares, by Product Segment, 2023
  • Figure 30 : Asia-Pacific Influenza Market Shares, by Country, 2023
  • Figure 31 : Chinese Influenza Market Shares, by Product Segment, 2023
  • Figure 32 : Japanese Influenza Market Shares, by Product Segment, 2023
  • Figure 33 : Indian Influenza Market Shares, by Product Segment, 2023
  • Figure 34 : Australian Influenza Market Shares, by Product Segment, 2023
  • Figure 35 : Rest of Asia-Pacific Influenza Market Shares, by Product Segment, 2023
  • Figure 36 : Rest of World Influenza Market Shares, by Product Segment, 2023
  • Figure 37 : Rest of World Influenza Market Shares, by Country, 2023
  • Figure 38 : South American Influenza Market Shares, by Product Segment, 2023
  • Figure 39 : Middle Eastern and African Influenza Market Shares, by Product Segment, 2023
  • Figure 40 : Company Share Analysis of Influenza Vaccine Market, 2023
  • Figure 41 : Company Share Analysis of Influenza Diagnostics Market, 2023
  • Figure 42 : Company Share Analysis of Influenza Therapeutics Market, 2023
  • Figure 43 : Abbott: Revenue Shares, by Business Unit, FY 2023
  • Figure 44 : Abbott: Revenue Shares, by Country/Region, FY 2023
  • Figure 45 : AstraZeneca: Revenue Shares, by Business Unit, FY 2023
  • Figure 46 : AstraZeneca: Revenue Shares, by Region/Country, FY 2023
  • Figure 47 : BD: Revenue Shares, by Business Unit, FY 2023
  • Figure 48 : BD: Revenue Shares, by Country/Region, FY 2023
  • Figure 49 : BioCryst Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2023
  • Figure 50 : BioCryst Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
  • Figure 51 : CSL: Revenue Shares, by Business Unit, FY 2023
  • Figure 52 : CSL: Revenue Shares, by Country/Region, FY 2023
  • Figure 53 : Daiichi Sankyo Co. Ltd.: Revenue Shares, by Business Unit, FY 2023
  • Figure 54 : Daiichi Sankyo Co. Ltd.: Revenue Shares, by Country/Region, FY 2023
  • Figure 55 : Danaher Corp.: Revenue Shares, by Business Unit, FY 2023
  • Figure 56 : Danaher Corp.: Revenue Shares, by Region/Country, FY 2023
  • Figure 57 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
  • Figure 58 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
  • Figure 59 : GSK Plc.: Revenue Shares, by Business Unit, FY 2023
  • Figure 60 : GSK Plc.: Revenue Shares, by Country/Region, FY 2023
  • Figure 61 : Hologic Inc.: Revenue Shares, by Business Unit, FY 2023
  • Figure 62 : Hologic Inc.: Revenue Shares, by Country/Region, FY 2023
  • Figure 63 : QuidelOrtho Corp.: Revenue Shares, by Business Unit, FY 2023
  • Figure 64 : QuidelOrtho Corp.: Revenue Shares, by Country/Region, FY 2023
  • Figure 65 : Sanofi: Revenue Shares, by Business Unit, FY 2023
  • Figure 66 : Sanofi: Revenue Shares, by Country/Region, FY 2023
  • Figure 67 : Thermo Fisher Scientific Inc.: Revenue Shares, by Business Unit, FY 2023
  • Figure 68 : Thermo Fisher Scientific Inc.: Revenue Shares, by Country/Region, FY 2023
  • Figure 69 : Viatris Inc.: Revenue Shares, by Business Unit, FY 2023
  • Figure 70 : Viatris Inc.: Revenue Shares, by Country/Region, FY 2023